A phase I/II clinical trial investigating the adverse and therapeutic effects of a postoperative autologous dendritic cell tumor vaccine in patients with malignant glioma
- 31 August 2011
- journal article
- Published by Elsevier BV in Journal of Clinical Neuroscience
- Vol. 18 (8), 1048-1054
- https://doi.org/10.1016/j.jocn.2010.11.034
Abstract
No abstract availableKeywords
This publication has 21 references indexed in Scilit:
- DENDRITIC CELL VACCINATION IN PATIENTS WITH MALIGNANT GLIOMASNeurosurgery, 2006
- Dendritic Cell Vaccination in Glioblastoma Patients Induces Systemic and Intracranial T-cell Responses Modulated by the Local Central Nervous System Tumor MicroenvironmentClinical Cancer Research, 2005
- Tumor lysate and IL-18 loaded dendritic cells elicits Th1 response, tumor-specific CD8+ cytotoxic T cells in patients with malignant gliomaJournal of Neuro-Oncology, 2005
- Vaccination of Glioma Patients with Fusions of Dendritic and Glioma Cells and Recombinant Human Interleukin 12Journal of Immunotherapy, 2004
- Vaccination of recurrent glioma patients with tumour lysate-pulsed dendritic cells elicits immune responses: results of a clinical phase I/II trialBritish Journal of Cancer, 2003
- Survival following surgery and prognostic factors for recently diagnosed malignant glioma: data from the Glioma Outcomes ProjectJournal of Neurosurgery, 2003
- Results of a phase I clinical trial of vaccination of glioma patients with fusions of dendritic and glioma cellsCancer Immunology, Immunotherapy, 2001
- Mature dendritic cells boost functionally superior CD8+ T-cell in humans without foreign helper epitopesJCI Insight, 2000
- Dendritic Cell Vaccines for Cancer ImmunotherapyAnnual Review of Medicine, 1999
- Dendritic Cells as Adjuvants for Immune-mediated Resistance to TumorsThe Journal of Experimental Medicine, 1997